%20--%3e%3c!DOCTYPE%20svg%20PUBLIC%20'-//W3C//DTD%20SVG%201.1//EN'%20'http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd'%20[%20%3c!ENTITY%20st0%20'fill:%23267E9A;'%3e%3c!ENTITY%20st1%20'fill:%2378C9DA;'%3e%3c!ENTITY%20st2%20'fill:%23FFFFFF;'%3e%3c!ENTITY%20st3%20'fill:%23085580;'%3e%3c!ENTITY%20st4%20'fill:%2386C34A;'%3e%3c!ENTITY%20st5%20'fill:%232FBBCC;'%3e%3c!ENTITY%20st6%20'fill:%234C6F90;'%3e%3c!ENTITY%20st7%20'fill:%23194670;'%3e%3c!ENTITY%20st8%20'fill:%2307557E;'%3e%3c!ENTITY%20st9%20'fill:%23516E89;'%3e%20]%3e%3csvg%20version='1.1'%20id='Layer_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%2032%2032'%20style='enable-background:new%200%200%2032%2032;'%20xml:space='preserve'%3e%3cg%3e%3cg%3e%3crect%20x='10.3'%20y='14'%20style='&st5;'%20width='5'%20height='4.4'/%3e%3crect%20x='10.3'%20y='12'%20style='&st5;'%20width='11.4'%20height='1'/%3e%3crect%20x='16.4'%20y='14'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='15.8'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='17.5'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='19.3'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='10.3'%20y='19.3'%20style='&st5;'%20width='5'%20height='0.9'/%3e%3cg%3e%3cpath%20style='&st5;'%20d='M22.6,22.3H9.4c-0.6,0-1.2-0.5-1.2-1.2v-10c0-0.6,0.5-1.2,1.2-1.2h13.1c0.6,0,1.2,0.5,1.2,1.2v10%20C23.7,21.7,23.2,22.3,22.6,22.3z%20M9.4,10.8c-0.1,0-0.3,0.1-0.3,0.3v10c0,0.1,0.1,0.3,0.3,0.3h13.1c0.1,0,0.3-0.1,0.3-0.3v-10%20c0-0.1-0.1-0.3-0.3-0.3H9.4z'/%3e%3c/g%3e%3c/g%3e%3cpath%20style='&st5;'%20d='M16,30.2C8.2,30.2,1.8,23.8,1.8,16S8.2,1.8,16,1.8S30.2,8.2,30.2,16S23.8,30.2,16,30.2z%20M16,2.8%20C8.7,2.8,2.8,8.7,2.8,16S8.7,29.2,16,29.2S29.2,23.3,29.2,16S23.3,2.8,16,2.8z'/%3e%3c/g%3e%3c/svg%3e)
Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
China News
10/21/2026
BiosimilarsCell TherapyChinaClinical TrialCornealDealsDiagnosticFundingGene TherapyGlaucomaIndustryMyopiaNewsletterOptometryRegulationRetinaSurgical
October 2026 Ophthalmic News Briefs
Sagent Pharmaceuticals, of Schaumburg, Illinois, announced Sept. 22 the US launch of Zyogreen, the first FDA-approved ready-to-use indocyanine green (ICG) injection in the US. Sagent said conventio...
10/2/2026
BreakingCell TherapyChinaClinical TrialRetina
iRegene’s RP Cell Therapy Candidate Gets Green Light for Clinical Trials in China, US
China’s iRegene Therapeutics announced Sept. 29 that its cell therapy candidate targeting retinitis pigmentosa (RP) gained authorization from regulators to enter clinical trials in both China and t...
9/25/2026
BreakingChinaMyopiaRegulation
Chinese Regulators Accept NDA for Low-Dose Atropine Drop for Myopia from Santen
Japan’s Santen announced Sept. 14 that China’s National Medical Products Administration (NMPA) had accepted the new drug application (NDA) for STN1012700 (atropine sulfate ophthalmic solution 0.025...
9/22/2026
AIChinaDealsDry EyeEuropeGlaucomaIOLIndustryLow VisionMyopiaNewsletterPharmaPresbyopiaRetinaSurgical
September 2026 Ophthalmic News Briefs
UK-based Rayner reported Sept. 7 the launch of its Galaxy Hydrophobic spiral IOL. The lens will be available commercially in the EU in Q4-2026. The original Galaxy spiral IOL, a full range of visio...
9/18/2026
BreakingChinaDealsGlaucomaPharmaRegulation
Chinese Regulators Accept NDA for Glaucoma Drop from Nicox, Ocumension
France’s Nicox and partner Ocumension Therapeutics, of China, announced Sept. 11 that China’s National Medical Products Administration (NMPA) had accepted the new drug application (NDA) for NCX 470...
8/21/2026
BreakingCataractChinaFLACSGlaucomaLaserPresbyopiaRefractiveRetinaRevenueSurgical
Q2-2026 Ophthalmic Revenue Roundup for STAAR, Lensar, Iridex, and Lenz
STAAR Surgical, of Lake Forest, California, reported Aug. 12 that its Q2-2026 net sales were $93.5 million, a 111 percent increase over $44.3 million in Q2-2025. China sales in Q2-2026 were $52.3 m...
8/20/2026
CataractChinaClinical TrialCornealDealsDiagnosticDry EyeFundingGene TherapyGlaucomaIOLNewsletterPharmaRetinaSurgical
Tarsus Leads Latest Fundraising with $125 Million Private Placement
Tarsus Pharmaceuticals led recent ophthalmic fundraising efforts with a $125 million private placement for clinical development and commercial activities. Financing announced in the past four weeks...
8/20/2026
AllergyCataractChinaDealsDiagnosticDry EyeEuropeFundusGene TherapyGlaucomaIOLIndustryLow VisionMyopiaNewsletterPharmaPresbyopiaRefractiveRegulationRetinaSurgical
August 2026 Ophthalmic News Briefs
Bausch + Lomb announced July 16 that it had launched the EyeGility Inserter preloaded IOL delivery system in the US. The inserter is available now with the enVista Aspire intermediate-optimized mon...
8/14/2026
BreakingChinaDealsGlaucomaPharmaRegulation
Nicox Partner Ocumension Submits NDA in China for Glaucoma Drop
France’s Nicox announced Aug. 10 that its partner Ocumension Therapeutics, of China, had submitted a new drug application (NDA) to China’s National Medical Products Administration for NCX 470, a ni...
8/14/2026
BreakingChinaClinical TrialRetina
US FDA Gives Green Light to Trial of Ractigen’s saRNA Candidate in PVR
China’s Ractigen Therapeutics reported on July 31 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase I clinical trial of ...
7/21/2026
ChinaMeetingMyopiaNewsletter
China’s Myopia Prevention Success Could Reshape a Still-Expanding Market
Recent data presented at the 2026 World Ophthalmology Congress demonstrate that China’s myopia reduction efforts are working. Myopia reduction initiatives by Chinese government agencies call for co...
7/21/2026
AICataractChinaDealsDiagnosticDigitalFundusGlaucomaIOLIndustryNewsletterPharmaRefractiveRegulationRetinaSurgical
July 2026 Ophthalmic News Briefs
Johnson & Johnson reported June 15 that it would invest more than $1 billion in its Jacksonville, Florida, operations to scale US-based manufacturing, packaging, and distribution for its Acuvue con...
7/17/2026
BreakingChinaDry EyeRegulation
Hengrui’s Cyclosporine Eye Drop Formulation for Dry Eye Gains Approval in China
China’s Hengrui Pharmaceuticals and Germany’s Novaliq announced June 30 that China’s National Medical Products Administration had approved Heng Yi (0.1% cyclosporine ophthalmic solution) for dry ey...
6/19/2026
BreakingChinaDealsRefractiveSurgical
Aier Eye Hospital Group to Buy 25 VisuMax 800 Lasers from Zeiss
German company Carl Zeiss Meditec reported June 17 that the Aier Eye Hospital Group in China had agreed to buy 25 VisuMax 800 femtosecond lasers for its hospital locations starting this year. The V...
6/18/2026
CataractChinaDry EyeGlaucomaNewsletterRetina
Regulatory Changes, Off-Brand Competition Reshape Ophthalmic Market in China
Continued change is shifting the dynamics of the ophthalmic market in China, boosting revenue growth in some sectors while slowing it in others. Changes are both regulatory and competitive. Regulat...
6/18/2026
ChinaDealsNewsletterPresbyopia
Everest Acquires Rights in Greater China to Lenz’ Vizz for Presbyopia
Everest Medicines, of Shanghai, China, has acquired rights in Greater China to Lenz Therapeutics’ Vizz (LNZ100) eye drops for presbyopia, Lenz reported June 7. Lenz, of San Diego, California, said ...
6/12/2026
BreakingChinaDealsPresbyopia
Everest Acquires Rights in Greater China to Lenz’ Vizz for Presbyopia
Everest Medicines, of Shanghai, China, has acquired rights in Greater China to Lenz Therapeutics’ Vizz (LNZ100) eye drops for presbyopia, Lenz reported June 7. Lenz, of San Diego, California, said ...
5/14/2026
ChinaDealsGlaucomaNewsletterPharma
Santen to Market Five of AbbVie’s Glaucoma Drops in Mainland China
Japan’s Santen Pharmaceutical announced April 17 that its China subsidiary had entered into a distribution and promotion agreement with AbbVie for five marketed glaucoma eye drops in the Chinese ma...
4/24/2026
BreakingChinaDealsGlaucomaPharma
Santen to Market Five of AbbVie’s Glaucoma Drops in China
Japan’s Santen Pharmaceutical announced April 17 that its China subsidiary had entered into a distribution and promotion agreement with AbbVie for five marketed glaucoma eye drops in the Chinese ma...
4/21/2026
ChinaClinical TrialEmergingGlaucomaIOLNewsletterProsthesisRetina
Emerging Companies Pursuing Ophthalmic Indications, April 2026
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
4/21/2026
BiosimilarsCataractCell TherapyChinaClinical TrialCornealDiagnosticDigitalDry EyeIOLIndiaIndustryMicroscopesNewsletterPharmaRegulationRetina
April 2026 Ophthalmic News Briefs
Swiss ophthalmic diagnostics company Haag-Streit announced March 31 the global launch of its Metis 3D Digital Heads-Up Module (Metis HU). The system was launched in the US in October 2025. Metis HU...
4/10/2026
BreakingChinaRefractiveRevenueSurgical
STAAR Surgical Reports Preliminary Q1-2026 Net Sales of More Than $90 Million
STAAR Surgical, of Lake Forest, California, reported April 8 that its Q1-2026 net sales were expected to be inexcess of $90 million, compared with $42.6 million in Q1-2025. STAAR’s Q1-2024 revenue ...
4/3/2026
BreakingChinaFundingStudy
China Gaining on US for Leadership in Early-Stage Drug Development, Georgetown Researchers Report
Early-stage drug development has increased dramatically over the past decade, with China gaining the most ground and challenging the US for leadership, according to Georgetown University. Georgetow...
3/27/2026
BreakingChinaDealsDry EyeRegulation
Regulators in China Approve Lotilaner Drops, Triggering $15 Million Payment to Tarsus
Tarsus Pharmaceuticals announced March 23 that regulators in China had approved TP-03 (lotilaner ophthalmic solution) 0.25%, its mite-killing treatment targeting Demodex blepharitis that is markete...
3/24/2026
ChinaCornealGlaucomaMeetingMyopiaNewsletter
2026 APAO Meeting in Hong Kong Attracts Surgeons from 111 Countries
Over 11 thousand eye care professionals met Feb. 4-7 in Hong Kong to exchange ideas and debate the strategies for managing eye diseases at the 2026 congress of the Asia-Pacific Academy of Ophthalmo...
3/27/2026
BreakingChinaClinical TrialRetina
Innovent Reports Positive Phase III Results for Extended-Dosing Retinal Candidate
China’s Innovent Biologics reported March 23 that IBI302 (efdamrofusp alfa), its extended-dosing retinal candidate, met its primary visual acuity endpoint at week 52 in the Phase III STAR study. IB...
3/24/2026
ChinaIndustryMeetingNewsletter
CCOI’s Innovation Meeting Shines Light on Untapped Assets in China
The Collaborative Community on Ophthalmic Innovation (CCOI) held a two-day meeting in Hong Kong prior to the 2026 APAO congress. The CCOI dedicated one day of its meeting to myopia and the other da...
3/20/2026
BreakingChinaDeviceEmerging
Super Vision Gains China Approval of i-NYS Implant for Congenital Nystagmus
China-based Super Vision reported March 16 that its i-NYS implantable device forcongenital nystagmus had received market approval from China’s National Medical Products Administration (NMPA). Super...
2/12/2026
BreakingChinaDealsIOLRefractiveSurgical
Arctic Vision to Acquire MDCO Technology’s Ophthalmic Device Business
China’s Arctic Vision announced Feb. 2 that it would acquire the ophthalmic device business of MDCO Technology. Arctic Vision said MDCO markets a premium intraocular lens (IOL), a phakic lens, and ...
1/21/2026
ChinaFundingGene TherapyNewsletterRetina
Kodiak Leads Latest Ophthalmic Fundraising with $184 Million Offering
Kodiak Sciences led recent ophthalmic fundraising efforts with a $184 million public offering to advance its Phase III candidates for retinal disease. Financing announced in the past four weeks tot...
1/9/2026
BreakingChinaClinical TrialCornealGene TherapyRegulation
US FDA Gives Green Light to Trial of GenEdit Bio’s Corneal Gene-Editing Candidate
GenEditBio reported on Jan. 5 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase I/II trial of GEB-101, its gene-editing ...
1/9/2026
BreakingChinaClinical TrialRegulationRetina
VivaVision Needs Single US Phase III Trial for Uveitis NDA, FDA Says
VivaVision Biotech reported Jan. 6 that minutes from its meeting with the US FDA confirm that its ongoing Phase III study in China can serve as one of the two pivotal trials required to support a U...
12/16/2025
BiosimilarsChinaDealsDiagnosticEuropeGene TherapyGlaucomaIndustryNewsletterOcular SurfaceRegulationRetina
December 2025 Ophthalmic News Briefs
Topcon Healthcare announced on Nov. 18 the FDA 510(k) clearance and US commercial launch of the TRK-3 Omnia, an automated four-in-one diagnostic device that integrates objective refraction, keratom...
11/19/2025
ChinaDealsNewsletterRetina
Novartis Offloads Rights to Beovu, Lucentis in South Korea, China
Swiss drugmaker Novartis made deals in October to offload distribution rights to retinal treatments Beovu (brolucizumab) and Lucentis (ranibizumab) in South Korea and mainland China. Japan’s Santen...
11/19/2025
AIBiosimilarsChinaClinical TrialDealsDiagnosticEuropeGene TherapyIndustryNewsletterPerimetryPresbyopiaRegulationRetinaThyroid Eye DiseaseUveitis
November 2025 Ophthalmic News Briefs
VEO Ophthalmics announced Oct. 16 that the VisionOne VR Visual Field platform is now available in the US through a strategic partnership with Switzerland’s PeriVision. No financial details about th...
11/19/2025
ChinaCornealDealsDiagnosticDry EyeEmergingNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, November 2025
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
11/7/2025
BreakingChinaDealsGene TherapyRetina
4DMT Licenses Retinal Gene Therapy Candidate to Otsuka for Asia-Pacific
4D Molecular Therapeutics announced Oct. 30 a strategic partnership with Otsuka Pharmaceutical Co. to develop and commercialize retinal gene therapy candidate 4D-150 in the greater Asia-Pacific (AP...
11/7/2025
BreakingChinaDealsIndustryPharmaRetina
Visara Licenses Retinal Candidate to Everest for Greater China, Other Asian Countries
NovaBridge Biosciences announced Oct. 29 that its ophthalmic subsidiary, Visara, had licensed retinal treatment candidate VIS-101 to Everest Medicines for greater China, Singapore, South Korea, and...
10/31/2025
BreakingChinaDealsPharmaRetina
China Medical System Acquires Rights in China to Novartis’ Beovu and Lucentis
China Medical System Holdings of Hong Kong announced Oct. 27 that its ophthalmic subsidiary CMS Vision had acquired exclusive distribution rights in mainland China for Novartis’ retinal treatments ...
10/24/2025
BreakingChinaDealsGene TherapyRetina
AviadoBio Signs Option to License UgeneX’ Optogenetics Gene Therapy Candidate
UK-based AviadoBio announced Oct. 9 that it had signed an option agreement to license UGX-202, an AAV-based optogenetic treatment candidate targeting retinitis pigmentosa, from China’s UgeneX Thera...
10/23/2025
ChinaGlaucomaMIGSNewsletterSurgical
Nova Eye’s iTrack Advance Canaloplasty Device Approved in China
Australia’s Nova Eye Medical announced Sept. 30 that China’s National Medical Products Administration had approved the marketing of the company’s iTrack Advance canaloplasty device for glaucoma. Th...
10/23/2025
BiosimilarsCataractChinaCornealDealsDiagnosticDry EyeEuropeGene TherapyGenericsGlaucomaIndiaIndustryMIGSNewsletterPharmaPresbyopiaRegulationRetinaSurgical
October 2025 Ophthalmic News Briefs
Biotech Healthcare announced Sept. 23 that it had launched the Optiflex Xtense Comfort Plus extended-depth-of-focus (EDOF) intraocular lens at the ESCRS 2025 congress in Copenhagen, Denmark. Biotec...
10/10/2025
BreakingChinaGlaucomaRegulationSurgical
Nova Eye’s iTrack Advance Canaloplasty Device Approved in China
Australia’s Nova Eye Medical announced Sept. 30 that China’s National Medical Products Administration had approved the marketing of the company’s iTrack Advance canaloplasty device for glaucoma. Th...
10/10/2025
BreakingChinaPharmaRegulationRetina
Regulators in China Accept BLA for DME Candidate from Santen, RemeGen
Japan’s Santen Pharmaceutical and partner RemeGen announced Sept. 30 that China’s Center for Drug Evaluation had accepted the biologic license application (BLA) for retinal treatment candidate RC28...
8/22/2025
BreakingChinaDealsPharmaRetina
Santen Licenses RemeGen’s Retinal Candidate for Greater China, Asian Countries
RemeGen announced Aug. 18 that Santen China, a subsidiary of Japan’s Santen Pharmaceutical, had licensed retinal treatment candidate RC28-E for Greater China and certain other Asian countries. Reme...
7/22/2025
ChinaNewsletterRegulation
Chinese Companies Launch Wave of New Ophthalmic Products at Home
China’s ophthalmic market is riding a wave of new Chinese offerings, spurred on by policies promoting the locali-zation of medical products. New products from Chinese companies approved by the Nati...
7/22/2025
AICell TherapyChinaDiagnosticEmergingGene TherapyNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, July 2025
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
7/22/2025
BiosimilarsCataractCell TherapyChinaClinical TrialDealsDiagnosticDry EyeEuropeFundingFundusGene TherapyGlaucomaNewsletterPharmaPresbyopiaRegulationRetinaSurgical
July 2025 Ophthalmic News Briefs
Hoya Vision Care announced June 2 that it had acquired Centennial Optical, a Canadian distributor of ophthalmic frames, eyeglass lenses, sunglasses, lab supplies, and optical accessories. Financial...
7/11/2025
BreakingChinaDry EyeRegulation
Chinese Regulators Approve Perfluorohexyloctane Drops for Dry Eye with MGD
China’s Hengrui Pharmaceuticals and Germany’s Novaliq announced July 8 that China’s National Medical Products Administration had approved Heng Qin (perfluorohexyloctane eye drops) for dry eye assoc...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.